These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. Adigun AQ, Ishola DA, Akintomide AO, Ajayi AA. J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973 [Abstract] [Full Text] [Related]
3. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. Johannesson M. J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040 [Abstract] [Full Text] [Related]
4. Economic costs and benefits of treating mild hypertension: results from a cross-sectional model. Millar JA, Hansen PC. N Z Med J; 1988 Oct 12; 101(855):623-5. PubMed ID: 3140147 [Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Circulation; 2005 Dec 06; 112(23):3569-76. PubMed ID: 16330698 [Abstract] [Full Text] [Related]
6. ESH-ESC guidelines for the management of hypertension. Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B. Herz; 2006 Jun 06; 31(4):331-8. PubMed ID: 16810473 [Abstract] [Full Text] [Related]
7. [Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines]. Fender P, Guilhot J, Tilly B, Salanave B, Allemand H. Therapie; 2001 Jun 06; 56(2):111-8. PubMed ID: 11471361 [Abstract] [Full Text] [Related]
8. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark]. Keiding H, Hildebrandt P, Burke T, Carides GW. Ugeskr Laeger; 2006 Oct 16; 168(42):3623-6. PubMed ID: 17069726 [Abstract] [Full Text] [Related]
9. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. McInnes G, Burke TA, Carides G. J Hum Hypertens; 2006 Jan 16; 20(1):51-8. PubMed ID: 16357874 [Abstract] [Full Text] [Related]
18. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands. Kok L, Engelfriet P, Jacobs-van der Bruggen MA, Hoogenveen RT, Boshuizen HC, Verschuren MW. Eur J Cardiovasc Prev Rehabil; 2009 Jun 16; 16(3):371-6. PubMed ID: 19305351 [Abstract] [Full Text] [Related]